- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Financial Sector
U.S. Pharmaceuticals & Biotech Financial Sector
UPDATED Feb 03, 2024
All the companies in the financial sector, including banks, mortgage and thrifts, capital markets, consumer finance and diversified financial services.
1,252 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ALKSAlkermes | US$26.74 | -3.6% | -2.2% | US$4.5b | US$33.09 | PE20.8x | E10.2% | n/a | ||
| SYNHSyneos Health | US$42.98 | 0.6% | -8.8% | US$4.5b | US$42.63 | PE62.6x | E33.7% | n/a | ||
| HALOHalozyme Therapeutics | US$33.68 | -1.5% | -36.0% | US$4.4b | US$47.50 | PE17.5x | E20.1% | n/a | ||
| AXSMAxsome Therapeutics | US$92.82 | 3.3% | 35.1% | US$4.4b | US$120.13 | PS19.7x | E57.7% | n/a | ||
| PRGOPerrigo | US$32.28 | -3.5% | -13.2% | US$4.4b | US$44.75 | PE412.7x | E45.2% | 3.4% | ||
| MDGLMadrigal Pharmaceuticals | US$220.28 | -2.5% | -21.3% | US$4.3b | US$321.08 | PB195.5x | E60.7% | n/a | ||
| OGNOrganon | US$16.64 | -0.5% | -44.1% | US$4.3b | US$20.44 | PE7.3x | E24.5% | 6.7% | ||
| SHCSotera Health | US$15.04 | 0.4% | -17.1% | US$4.3b | US$16.83 | PS4.3x | E97.3% | n/a | ||
| ALVOAlvotech | US$15.70 | 7.2% | 27.9% | US$4.2b | US$12.33 | PS65.4x | E78.1% | n/a | ||
| ACADACADIA Pharmaceuticals | US$25.29 | -6.1% | 27.5% | US$4.2b | US$34.25 | PS6.6x | E47.2% | n/a | ||
| MRTXMirati Therapeutics | US$58.70 | -0.5% | 18.9% | US$4.1b | US$61.00 | PS107.8x | E29.9% | n/a | ||
| INSMInsmed | US$28.18 | 1.7% | 30.5% | US$4.0b | US$42.54 | PS14.4x | E41.0% | n/a | ||
| ARWRArrowhead Pharmaceuticals | US$31.96 | -2.4% | -13.0% | US$4.0b | US$54.25 | PS16.4x | E19.0% | n/a | ||
| TPTXTurning Point Therapeutics | US$76.01 | 1.3% | 18.9% | US$3.8b | US$76.00 | PS3776x | E24.7% | n/a | ||
| RYZBRayzeBio | US$62.12 | 0.06% | n/a | US$3.7b | US$47.45 | PB6.5x | E0.8% | n/a | ||
| AZTAAzenta | US$66.10 | 0.9% | 13.4% | US$3.7b | US$72.00 | PS5.5x | E43.2% | 0% | ||
| FOLDAmicus Therapeutics | US$12.44 | 0.8% | -6.1% | US$3.6b | US$19.56 | PS9.8x | E55.9% | n/a | ||
| IMCRImmunocore Holdings | US$73.74 | 5.4% | 14.7% | US$3.6b | US$81.89 | PS15x | E26.7% | n/a | ||
| BHVNBiohaven | US$44.79 | -0.2% | 146.2% | US$3.6b | US$44.50 | PB12.4x | E19.1% | n/a | ||
| RAREUltragenyx Pharmaceutical | US$43.02 | -4.3% | -5.9% | US$3.5b | US$90.75 | PS8.6x | E44.8% | n/a | ||
| XENEXenon Pharmaceuticals | US$45.92 | 0.6% | 17.2% | US$3.5b | US$54.41 | PB5.5x | E26.5% | n/a | ||
| SWTXSpringWorks Therapeutics | US$46.16 | 8.9% | 45.6% | US$3.4b | US$57.17 | PB8.6x | E21.5% | n/a | ||
| MLTXMoonLake Immunotherapeutics | US$55.25 | -3.4% | 358.5% | US$3.3b | US$69.00 | PB7.8x | E1.6% | n/a | ||
| ACLXArcellx | US$63.54 | 1.1% | 94.3% | US$3.3b | US$65.73 | PS69.9x | E3.6% | n/a |